| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 381,8 k € | — | — | — | — | 183,1 k € | — | 191,9 k € | — | — | 27,7 k € | -32.5% | 41,1 k € | |||||||||||
| Gross margin | 192,5 k € | +683.1% | 24,6 k € | +369.6% | -9,1 k € | -108.4% | 108,9 k € | -2.1% | 111,2 k € | +56.8% | 70,9 k € | +142.8% | 29,2 k € | -46.0% | 54,1 k € | -16.1% | 64,4 k € | +335.5% | 14,8 k € | +162.8% | 5,6 k € | +75.4% | 3,2 k € | |
| EBITDA | 12,0 k € | -51.2% | 24,6 k € | +333.0% | -10,5 k € | -109.9% | 106,3 k € | -1.9% | 108,3 k € | +57.0% | 69,0 k € | +799.2% | -9,9 k € | -126.5% | 37,2 k € | -39.7% | 61,7 k € | +327.3% | 14,4 k € | +194.5% | 4,9 k € | +199.6% | 1,6 k € | |
| Operating profit | -23,0 k € | -193.6% | 24,6 k € | +174.8% | -32,9 k € | -136.5% | 90,0 k € | +9.8% | 82,0 k € | +77.4% | 46,2 k € | +277.1% | -26,1 k € | -205.4% | 24,8 k € | -49.3% | 48,8 k € | +522.3% | 7,8 k € | +92.8% | 4,1 k € | +148.7% | 1,6 k € | |
| Profit/loss | -24,3 k € | -267.6% | 14,5 k € | +143.5% | -33,3 k € | -149.0% | 67,9 k € | +5.1% | 64,6 k € | +77.1% | 36,5 k € | +228.2% | -28,5 k € | -290.3% | 15,0 k € | -66.4% | 44,5 k € | +2172.2% | 2,0 k € | -32.2% | 2,9 k € | +56.7% | 1,8 k € | |
| Equity | 141,1 k € | -14.7% | 165,4 k € | +9.6% | 150,9 k € | -26.1% | 204,2 k € | +49.8% | 136,4 k € | +90.0% | 71,8 k € | +103.4% | 35,3 k € | -44.7% | 63,7 k € | +30.7% | 48,8 k € | +1048.7% | 4,2 k € | -61.2% | 10,9 k € | +35.9% | 8,0 k € | |
| Total assets | 391,3 k € | +30.0% | 301,0 k € | +57.1% | 191,6 k € | -23.1% | 249,1 k € | +45.2% | 171,5 k € | +60.0% | 107,2 k € | +1.9% | 105,2 k € | +7.3% | 98,1 k € | -27.7% | 135,6 k € | +351.4% | 30,0 k € | +52.9% | 19,6 k € | +30.9% | 15,0 k € | |
| Cash | 49,5 k € | -68.3% | 155,9 k € | +171.0% | 57,5 k € | -11.3% | 64,8 k € | -18.2% | 79,2 k € | +100.1% | 39,6 k € | +102.1% | 19,6 k € | -10.1% | 21,8 k € | -71.2% | 75,8 k € | +428.3% | 14,3 k € | +116.5% | 6,6 k € | +9.2% | 6,1 k € | |
| Debts | 250,1 k € | +84.6% | 135,5 k € | +233.5% | 40,6 k € | -9.4% | 44,8 k € | +27.4% | 35,2 k € | -0.7% | 35,5 k € | -49.3% | 70,0 k € | +103.7% | 34,4 k € | -60.4% | 86,8 k € | +236.6% | 25,8 k € | +196.1% | 8,7 k € | +25.0% | 7,0 k € | |
Source: Belgian Official Gazette
Private company with limited liability · Liège · incorporated on 12/02/2013
Private company with limited liability loss-making in the latest fiscal year. Cash position declining (-68.3%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
RB PHARMA is a Private company with limited liability incorporated in 2013. Its main activity is: Management consultancy activities. Its registered office is in Liège.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.